semaglutide prediabetes progression to diabetes step trial For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral at a dose of 50 mg Three new phase 3 REIMAGINE

These Authors failed to evidence significant changes in indexes of insulin resistance and speculated that other classical effects of GLP-1 RA, such as suppressed glucagon secretion, with consequent reduced hepatic glucose production, could have been involved in the improvement in glucose metabolism and ectopic fat deposition [54]

That's not a finding suggesting GLP-1s should be avoided - it's a finding suggesting that musculoskeletal support, including resistance training, isn't optional for women on these medications

For most conditions, a patient can collect a months worth of pills and manage their own dosage schedule within a safe range, often a week or more in advance of needing them

10.1016/j.pneurobio.2016.10.001 Prog

Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis

Read More Key Insights The current range of weight-loss drugs on the market targets GLP-1 receptors